Skip to main content
. 2020 Mar 9;295(15):4937–4949. doi: 10.1074/jbc.RA119.010498

Figure 6.

Figure 6.

MyHC IIA/X-AS sponges miR-130b as a ceRNA. A, potential miR-130b–binding site in MyHC IIA/X-AS was predicted using RegRNA2.0. B, statistical results of Dual-Luciferase reporter assay (n = 3). C, expression profile of miR-130b during in vitro myogenic differentiation was tested through qRT-PCR (n = 3). D, changes of MyHC IIA/X-AS upon exogenous overexpression of miR-130b were estimated through qRT-PCR in myotubes 6 days post-myogenic differentiation (n = 5). E, expression of miR-130b was significantly altered in myotubes transfected with MyHC IIA//X-AS siRNA (n = 3). F, enrichment of MyHC IIA/X-AS and miR-130b was determined through qRT-PCR in Ago2-RIP assay (n = 3). G, level of MyHC IIA/X-AS mRNA immunoprecipitated by biotin-labeled miR-130b or miR-130b–Mut probes was detected through qRT-PCR (n = 3). NC, negative control. *, p < 0.05; **, p < 0.01.